Artrya Limited (ASX: AYA) shares are having a good start to the day. In morning trade, the ASX tech stock is up 6% to $4.10. Why is this ASX tech stock X? Investors have been bidding Artrya's shares higher after it announced another customer win in the United States. Artrya is a medical technology company developing artificial intelligence (AI)-powered solutions to improve the detection and management of coronary artery disease. It notes that its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease. This supports clinicians in diagnosing patients more accurately and efficiently. The company states that its mission is to advance cardiac care through Innovative technology, with regulatory, and commercial activities underway across key international markets. What did it announce? This morning, the ASX tech stock announced its third U.S. commercial customer, with the signing of a commercial agreement with Cone Health for the use of its Salix platform. The five-year agreement has a minimum value of US$0.45 million for the use of the Salix Coronary Anatomy platform, with additional per-scan revenue from Salix Coronary Plaque module. Salix will be fully integrated across Cone Health's network of hospitals and cardiology practices. This means that it has successfully completed the conversion of all three U.S. foundation partners to commercial customers in 2025. Commenting on the contract win, the ASX tech stock's co-founder and CEO, John Konstantopoulos, said: We are very pleased to secure Cone Health, one of North Carolina's leading healthcare networks, as our third U.S. commercial customer. We have now successfully converted all three of our foundation partners to commercial customers, which highlights the benefits of our partner collaborations to validate the clinical and commercial use of Salix. This also shows our growing commercial momentum as move into 2026, where we will focus on growing the use of the Salix® platform and plaque module throughout our customer base. Cone Health's Medical Director of Cardiac CT and Nuclear Cardiology, Dr. Wesley O'Neal, MD, adds: We are delighted to build on our successful collaboration with Artrya and bring this transformative Salix technology into the clinical workflow across our network. Through this process we can see major benefits in the way that Salix can provide accurate, point-of-care interpretation of CCTA scans within minutes, enabling our team to deliver faster, more precise diagnoses for our patients. Moving forward we believe this will advance patient care across our network. Artrya shares are now up approximately 80% over the past three months.